arch27
EN_01270334_1839
Bruce Fenstermacher meets with Dr. Wassim Abida as he begins a clinical trial of an experimental drug that could target a rare mutation in his cancer, at the Memorial Sloan Kettering Cancer Center in New York, Feb. 8, 2017. Breakthroughs in immunotherapy and a rush to develop profitable new treatments have brought a crush of clinical trials scrambling for patients. (George Etheredge/The New York Times)
MINIMALNA CENA 100USD!!!
2017-02-08
GEORGE ETHEREDGE/The New York Ti/EAST NEWS
The New York Times Agency
GEORGE ETHEREDGE
h_14994276
1,82MB
28cm x 19cm by 300dpi
2017, 8, A, ABIDA, AMERICA, AN, AND, AS, AT, BEGINS, BREAKTHROUGHS, BROUGHT, BRUCE, CANCER, CENTER, CLINICAL, COULD, CRUSH, DEVELOP, DR, DRUG, ETHEREDGE, EXPERIMENTAL, FEB, FENSTERMACHER, FOR, GEORGE, HAVE, HE, HIS, IMMUNOTHERAPY, IN, KETTERING, MEDICAL, MEDICINE, MEETS, MEMORIAL, MUTATION, NATIONAL, NEW, NORTH, OF, PATIENTS, PROFITABLE, RARE, RUSH, SCIENCE, SCRAMBLING, SLOAN, TARGET, THAT, THE, TIMES, TO, TREATMENTS, TRIAL, TRIALS, WASSIM, WITH, YORK,